Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

Wendel Naumann, R.; Hollebecque, Antoine; Meyer, Tim; Devlin, Michael-John; Oaknin, Ana; Kerger, Joseph; M. López-Picazo, José; Machiels, Jean-Pascal; Delord, Jean‐Pierre; Jeffry Evans, T.R.; Boni, Valentina; Calvo, Emiliano; L. Topalian, Suzanne; Chen, Tian; Soumaoro, Ibrahima; Li, Bin; Gu, Junchen; Zwirtes, Ricardo; N. Moore, Kathleen

doi:10.1200/jco.19.00739

Public

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

Published in Journal of Clinical Oncology • Sep 5, 2019

Authors:

R. Wendel Naumann

Antoine Hollebecque

Tim Meyer

Abstract

PURPOSE: Nivolumab was assessed in patients with virus-associated tumors in the phase I/II CheckMate 358 trial (ClinicalTrials.gov identifier: NCT02488759). We report on patients with recurrent/metastatic cervical, vaginal, or vulvar cancers. PATIENTS AND METHODS: Patients received nivolumab 240 mg ...

Subject

Medicine

Vulvar cancer

Vulvar Carcinoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!